drugset / Trial / NCT00035165

EPO906 Therapy in Patients With Advanced Melanoma

NCT00035165

Phase 2 Completed 51 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.

Timeline

Start
2002-03
Primary completion
2003-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule 2.5 mg/m2 Intravenous

Indications